Critical Illness, Vitamin D Deficiency
Conditions
Keywords
Vitamin D Deficiency, Critical Illness
Brief summary
Vitamin D has been shown to related to clinical outcomes in critically ill patients. The object of this study is to investigate the prevalence of Vitamin D deficiency in critically ill patients with various length of ICU stay .
Detailed description
Studies have revealed that the serum level of 25-hydroxyvitamin D, as known as calcidiol, is low in critically ill patients. The prevalence ranges from 26 to 82%. 25-hydroxyvitamin D deficiency is associated with longer ICU stay, higher medical cost and higher death rate in septic patients. 25-hydroxyvitamin D is a kind of hormone related to bone and mineral metabolism. Moreover, the receptors were found in almost all cells, and it is related to immune system, cytokine release, cellular proliferation and differentiation, angiogenesis, and muscular energy. The main source is skin metabolism triggered by sunshine and food consumption. It is subsequently converted to calcifediol in the liver and then calcitriol in the kidney (the active form). Its serum level is regulated by parathyroid hormone and serum calcium and phosphate. The critically ill patients are deprived of sunshine, suffered from poor nutrition support, impaired liver and kidney function, higher rate of consumption, and are under higher risk of deficiency. Nowadays, the studies about 25-hydroxyvitamin D in ICU patients were conducted mostly in Europe and America. There is no large-scale study in Taiwan or Asia. A randomized controlled study from Austria has shown large dose supply in patients with 25-hydroxyvitamin D deficiency could decrease the mortality. The object of this multi-center study is to investigate the prevalence of 25-hydroxyvitamin D deficiency, the risk factors and the correlation with outcomes. The results could be a step-stone for future randomized controlled studies.
Interventions
None listed
Sponsors
National Taiwan University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All ICU patients
Exclusion criteria
* 1, Less than 20 years 2, BMI \< 18 kg/m\^2 3, Had large dose vit D within previous four weeks (over 3000 IU per day) 4, ICU admission within previous three months 5, Have disease affecting vit D level, calcium metabolism, bone metabolism such as parathyroid disease, Rickets, liver cirrhosis child C 6, Communication difficulty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The prevalence of Vitamin D deficiency | 1 day at enrollment | Investigate the prevalence of vitamin D deficiency among groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference of 28-day ventialtor-free days | 28 days | Compare the 28-day ventialtor-free days of patients with vitamin D deficiency and patients without vitamin D deficiency for all groups |
| Difference of 28-day ICU-free days | 28 days | Compare the 28-day ICU-free days of patients with vitamin D deficiency and patients without vitamin D deficiency for all groups |
| Difference of mortality on 28th and 90th day in group 2 | 90 days | Compare the mortality of 28th and 90th day of patients with vitamin D deficiency and patients without vitamin D deficiency in group 2 |
| Difference of mortality on 28th and 90th day in group 3, 4, and 5 | 90 days | Compare the mortality of 28th and 90th day of patients with vitamin D deficiency and patients without vitamin D deficiency in group 3, 4, and 5 |
| Serial changes of serum vitamin D levels in group 2 | 28 days | investigate the serum vitamin D levels at different time points in group 2 |
Countries
Taiwan
Outcome results
None listed